Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategic Spin-Outs: Biotechs Structure Their Progeny For Success

This article was originally published in Start Up

Executive Summary

Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.

You may also be interested in...



Spero Therapeutics LLC

Spero Therapeutics LLC was formed to develop antibiotics based on a novel mechanism, to treat infections with high unmet need. Its lead program, initiated in 2013, commercializes the research of Laurence Rahme of Mass General, who invented a method for using small molecules to inhibit MvfR, a transcription regulator utilized by gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella.

Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

Biopharma Dealmaking Quarterly Statistics, Q1 2014

Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092580

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel